2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in ...

2seventy's Q3, 10-Q (the "10-Q") addresses its Regeneron (REGN) deal at several locations. It characterizes the deal as a key component of its strategic realignment so it can focus on the ...

2seventy bio has sold its cell therapy pipeline and operations to Regeneron Pharmaceuticals for at least $15 million, as part of a restructuring that includes eliminating 14% of its workforce ...

2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed ...

2seventy bio will host a conference call and live webcast today, August 14, at 8:00 a.m. ET to discuss 2Q 2023 financial results and recent business highlights.

Shares of 2seventy bio, Inc. TSVT have rallied 51.4% in the past three months against the industry’s decrease of 7.6%. The company is developing and commercializing its chimeric antigen receptor ...

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced late-breaking results from the ongoing Phase 1 PLAT ...

This week, 2seventy bio Inc. and Bristol Myers Squibb halted a Phase 3 trial, the Healey-Driscoll administration has announced nearly $20 million in life sciences funding, and a Flagship spinout ...

2seventy bio, the cancer-focused spinout of bluebird bio, has paused a clinical trial in acute myeloid leukemia after a child died at Seattle Children's. Plus, other life sciences news you may ...

2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Recent positive results from the KarMMa-3 study ...